These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 12095174)

  • 21. Lack of interference of guanosine with ribavirin aerosol treatment of influenza A infection in mice.
    Knight V; Wilson SZ; Alling DW; Moore RV; Longoria RM
    Antimicrob Agents Chemother; 1981 Oct; 20(4):477-80. PubMed ID: 6282193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microneedle Vaccination Elicits Superior Protection and Antibody Response over Intranasal Vaccination against Swine-Origin Influenza A (H1N1) in Mice.
    Shin JH; Park JK; Lee DH; Quan FS; Song CS; Kim YC
    PLoS One; 2015; 10(6):e0130684. PubMed ID: 26086590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo influenza virus-inhibitory effects of viramidine.
    Sidwell RW; Bailey KW; Wong MH; Barnard DL; Smee DF
    Antiviral Res; 2005 Oct; 68(1):10-7. PubMed ID: 16087250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
    Maltais AK; Stittelaar KJ; Veldhuis Kroeze EJ; van Amerongen G; Dijkshoorn ML; Krestin GP; Hinkula J; Arwidsson H; Lindberg A; Osterhaus AD
    Vaccine; 2014 May; 32(26):3307-15. PubMed ID: 24690149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of intranasal and aerosol infection of mice in assessment of immunity to influenza virus infection.
    Johansson BE; Kilbourne ED
    J Virol Methods; 1991 Nov; 35(1):109-14. PubMed ID: 1666111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FimH, a TLR4 ligand, induces innate antiviral responses in the lung leading to protection against lethal influenza infection in mice.
    Abdul-Careem MF; Firoz Mian M; Gillgrass AE; Chenoweth MJ; Barra NG; Chan T; Al-Garawi AA; Chew MV; Yue G; van Roojen N; Xing Z; Ashkar AA
    Antiviral Res; 2011 Nov; 92(2):346-55. PubMed ID: 21945041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
    Onishi M; Kitano M; Taniguchi K; Homma T; Kobayashi M; Yoshinaga T; Naito A; Sato A
    Antiviral Res; 2015 May; 117():52-9. PubMed ID: 25752738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses.
    Jones JC; Marathe BM; Vogel P; Gasser R; Najera I; Govorkova EA
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.
    Dong W; Bhide Y; Sicca F; Meijerhof T; Guilfoyle K; Engelhardt OG; Boon L; de Haan CAM; Carnell G; Temperton N; de Vries-Idema J; Kelvin D; Huckriede A
    Front Immunol; 2018; 9():2312. PubMed ID: 30356772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation.
    Kadowaki S; Chen Z; Asanuma H; Aizawa C; Kurata T; Tamura S
    Vaccine; 2000 Jun; 18(25):2779-88. PubMed ID: 10812219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD47 Plays a Role as a Negative Regulator in Inducing Protective Immune Responses to Vaccination against Influenza Virus.
    Lee YT; Ko EJ; Lee Y; Lee YN; Bian Z; Liu Y; Kang SM
    J Virol; 2016 Aug; 90(15):6746-6758. PubMed ID: 27194758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
    Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
    J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A/WSN virus.
    Gilbert BE; Wyde PR; Wilson SZ; Robins RK
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1448-53. PubMed ID: 1929307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs.
    Chen Z; Matsuo K; Asanuma H; Takahashi H; Iwasaki T; Suzuki Y; Aizawa C; Kurata T; Tamura S
    Vaccine; 1999 Feb; 17(7-8):653-9. PubMed ID: 10067670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small-particle aerosols of antiviral compounds in treatment of type A influenza pneumonia in mice.
    Walker JS; Stephen EL; Spertzel RO
    J Infect Dis; 1976 Jun; 133 Suppl():A140-4. PubMed ID: 932501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.